

Center for Genetic Engineering and Biotechnology produces Abdala vaccine for those allergic to thiomersal



The Center for Genetic Engineering and Biotechnology has announced that the Abdala anti-COVID-19 vaccine is ready for those allergic to thiomersal over 19 years of age.

Havana, September 25 (RHC)-- The Center for Genetic Engineering and Biotechnology has announced that the Abdala anti-COVID-19 vaccine is ready for those allergic to thiomersal over 19 years of age.

The institution highlighted the news on its Twitter account, noting that this will allow immunizing individuals who are allergic to this substance and could not be included in the vaccinations from the first stage.

During this week, the vaccination against COVID-19 began for those allergic to thiomersal throughout the country, and it was also reported that children allergic to this compound will be inoculated in the next few days, since the necessary doses are already available and the pertinent organizational measures have been taken in vaccination center.

The Ministry of Public Health explained on its website that thiomersal or thimerosal is a component that was previously used to heal wounds and is present in many Cuban vaccines. In the case of multi-dose batches of Cuban immunogens, this compound works as a product preservative, hence the need to produce single-dose batches to dispense with the substance.

CIGB is a Cuban institution dedicated to the research, production and commercialization of biotechnological and pharmaceutical products, which it markets in more than 30 countries.

<https://www.radiohc.cu/en/noticias/nacionales/271564-center-for-genetic-engineering-and-biotechnology-produces-abdala-vaccine-for-those-allergic-to-thiomersal>



Radio Habana Cuba